MINNEAPOLIS, July 5, 2022 /PRNewswire/ -- Bio-Techne
Corporation (NASDAQ:TECH), today announced it has completed the
acquisition of Namocell, Inc. The Namocell acquisition adds
easy-to-use single cell sorting and dispensing platforms that are
gentle to cells and preserve cell viability and integrity.
Namocell's instruments and consumables are critical technologies in
various workflows in both biotherapeutics and diagnostics,
including cell and gene therapy development and commercialization,
cell engineering, cell line development, single cell genomics,
antibody discovery, synthetic biology, and rare cell isolation.
Forward Looking Statements:
Our press releases may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act. Such
statements involve risks and uncertainties that may affect the
actual results of operations. Forward looking statements in this
press release include statements regarding our belief about the
market applications and impact of our pending acquisition of
Namocell, Inc. and our ability to derive advantages from this
acquisition as we integrate it into our business. The following
important factors, among others, have affected and, in the future,
could affect the Company's actual results: the effect of new
branding and marketing initiatives, the integration of new
businesses and leadership, the introduction and acceptance of new
products, the funding and focus of the types of research by the
Company's customers, the impact of the growing number of producers
of biotechnology research products and related price competition,
general economic conditions, customer site closures or supply chain
issues resulting from the COVID-19 pandemic, the impact of currency
exchange rate fluctuations, and the costs and results of research
and product development efforts of the Company and of companies in
which the Company has invested or with which it has formed
strategic relationships.
For additional information concerning such factors, see the
section titled "Risk Factors" in the Company's annual report on
Form 10-K and quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission. We undertake no obligation to
update or revise any forward-looking statements we make in our
press releases due to new information or future events. Investors
are cautioned not to place undue emphasis on these statements.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact:
|
David Clair, Senior
Director, Investor Relations and Corporate Development
|
|
david.clair@bio-techne.com
|
|
612-656-4416
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-completion-of-namocell-acquisition-301580002.html
SOURCE Bio-Techne Corporation